{
    "clinical_study": {
        "@rank": "72271", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (not an active drug/ Inactive component) is given to this group"
            }, 
            {
                "arm_group_label": "VSL", 
                "arm_group_type": "Active Comparator", 
                "description": "VSL#3 (probiotic mixture) is given to this group"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective is to determine whether VSL#3\u00ae will improve 1) intestinal symptoms of\n      Irritable Bowel Syndrome (IBS) and 2) non-intestinal symptoms (fatigue, joint pain,\n      insomnia, general stiffness and headache) associated with IBS. All of these symptoms are\n      part of the Gulf War (GW) illness."
        }, 
        "brief_title": "Probiotic (VSL#3) for Gulf War Illness", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gulf War Illness", 
        "detailed_description": {
            "textblock": "Specific Aims:\n\n      Aim # 1: Determine the efficacy of VSL#3\u00ae on IBS symptoms in GW veterans.\n\n      Hypothesis: Treatment with VSL#3\u00ae compared to placebo will improve global and individual\n      symptoms of IBS\n\n      Aim #2 Determine the efficacy VSL#3\u00ae in reducing non-intestinal symptoms of IBS (fatigue,\n      joint pain, insomnia, general stiffness and headache).\n\n      Hypothesis: Treatment with VSL#3\u00ae compared to placebo will improve non-intestinal symptoms\n      of IBS in GW veterans.\n\n      Aim #3 Determine whether changes in gut flora and plasma cytokines correlate with treatment\n      response in GW veterans."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. First GW veterans, Men and women age 35-75 years,\n\n          2. Rome III criteria for IBS and two or more of the non-intestinal symptoms\n             (chronic-once a week or more often-fatigue, joint pains, insomnia, general stiffness,\n             and headache)\n\n          3. Symptoms of > 6 months duration,\n\n          4. No significant findings on physical examination, Complete Blood Count (CBC) and\n             clinical chemistry panel.\n\n          5. Normal gross appearance of the colonic mucosa other than erythema and polyps\n\n          6. Negative Tissue transglutaminase (TTG) for celiac disease,\n\n          7. Normal thyroid function.\n\n          8. Veterans with psychological disorders will not be excluded but will be identified for\n             sub-group analysis.\n\n          9. Stable medication regimen for more than a month\n\n        Exclusion Criteria:\n\n          1. Current evidence of any lower gastrointestinal disorder such as celiac disease or\n             inflammatory bowel disease\n\n          2. History of/or presence of systemic malignancy (patients with skin and other cancers\n             in remission for more than 5 years are allowed in the study\n\n          3. Clinically significant chronic disease: HIV, cardiac, pulmonary, hepatic or renal\n             dysfunction.\n\n          4. Presence of Giardia antigen, and Clostridium difficile toxin in stool,\n\n          5. Abnormal blood test for thyroid stimulating hormone, tissue transglutaminase antibody\n\n          6. Current effects of drug or alcohol abuse\n\n          7. Investigator perception of patient's inability to comply with study protocol\n\n          8. Recent change in gastrointestinal medications\n\n          9. Use of any antibiotic in the last 1 months\n\n         10. Positive pregnancy test\n\n         11. Subject is currently participating in another research protocol that could interfere\n             or influence the outcome measures of the present study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011542", 
            "org_study_id": "W81XWH-10-1-0593"
        }, 
        "intervention": [
            {
                "arm_group_label": "VSL", 
                "description": "This is a probiotic mixture", 
                "intervention_name": "VSL#3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "This is a pill  with inactive ingredients.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo/ Sugar pill"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GWI", 
            "IBS", 
            "Irritable Bowel Syndrome", 
            "Gulf War Illness"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "contact": {
                "email": "ashok.tuteja@va.gov", 
                "last_name": "Ashok K Tuteja, MD, MPH", 
                "phone": "801-582-1565", 
                "phone_ext": "4019"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84132"
                }, 
                "name": "George E Wahlen VA Medical Center"
            }, 
            "investigator": {
                "last_name": "Ashok K Tuteja, MD, MPH, MRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Probiotics (VSL#3) for Gulf War Illness", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy of VSL# 3 in IBS related symptoms in GW illness is measured using BSS at 2, 4, 6, 8 wks", 
            "measure": "Improvement in the Bowel symptom scale (BSS) from baseline", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011542"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Department of Veterans Affairs", 
            "investigator_full_name": "Ashok Tuteja", 
            "investigator_title": "Associate Professor Gastroenterology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Efficacy of VSL#3 in reducing non-intestinal symptoms of IBS is measured using chronic fatigue scale at 2,4,6,8, weeks", 
            "measure": "Change in chronic fatigue (1-5 scale) from baseline", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Department of Veterans Affairs", 
        "sponsors": {
            "collaborator": {
                "agency": "VSL Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}